Citi analyst Joel Beatty upgraded Solid to Neutral from Sell while lowering his price target for the shares to $8 from $31. The analyst says that with the initial clinical data for SGT-001 announced yesterday, his Sell thesis has played out. He moves to a Neutral rating because he believes that the next dosing cohort is “unlikely to generate strong enough data to support a commercially competitive profile.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.